Werewolf Therapeutics and Jazz Pharmaceuticals Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE™ Molecule April 8, 2022
Longwood Fund Announces Longwood Healthcare Leaders, a Web Conference for Industry Leaders, on May 4-5, 2022 March 30, 2022
Werewolf Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy of WTX-124 in Delivering IL-2 Selectively to the Tumor Microenvironment March 17, 2022
Green Journal Publishes Study Showing leva “Significantly Improved” Symptoms of Urinary Incontinence in Women versus Kegel Exercises Alone March 14, 2022
Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results Selected for an Oral Presentation at the 2022 AACR Annual Meeting March 11, 2022
